{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:24:39Z","timestamp":1793057079445,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.10.004","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:57:25Z","timestamp":1730743045000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-2517","authenticated-orcid":false,"given":"Yoseph","family":"Caraco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maor","family":"Wanounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simcha","family":"Blotnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lital","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2024.10.004_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.10.004_bib0002","first-page":"331","article-title":"An update on new and emerging therapies for cystic fibrosis","volume":"22","author":"Hudock","year":"2017"},{"key":"10.1016\/j.jcf.2024.10.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.jcf.2024.10.004_bib0004","doi-asserted-by":"crossref","unstructured":"Mrugacz M. Human genetic diseases. Plaseska-Karanfilska D, editor. InTech. 2011.","DOI":"10.5772\/904"},{"key":"10.1016\/j.jcf.2024.10.004_bib0005","first-page":"331","article-title":"An update on new and emerging therapies for cystic fibrosis","volume":"22","author":"Hudock","year":"2017"},{"key":"10.1016\/j.jcf.2024.10.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.jcf.2024.10.004_bib0007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8862","key":"10.1016\/j.jcf.2024.10.004_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(93)91885-P","article-title":"Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C \u2013>T mutation","volume":"342","author":"Augarten","year":"1993","journal-title":"The Lancet"},{"key":"10.1016\/j.jcf.2024.10.004_bib0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-9525(01)02619-1","article-title":"Splicing regulation as a potential genetic modifier","volume":"18","author":"Nissim-Rafinia","year":"2002","journal-title":"Trends in Genetics"},{"key":"10.1016\/j.jcf.2024.10.004_bib0010","doi-asserted-by":"crossref","unstructured":"Highsmith W.E., Burch L.H., Zhou Z., Olsen J.C., Boat T.E., Spock A., et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. 10.1056\/NEJM199410133311503. 2010 Jan 15;331(15):974\u201380.","DOI":"10.1056\/NEJM199410133311503"},{"issue":"11","key":"10.1016\/j.jcf.2024.10.004_bib0011","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.embor.7400273","article-title":"Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation","volume":"5","author":"Nissim-Rafinia","year":"2004","journal-title":"EMBO Rep"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.004_bib0012","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.jcf.2024.10.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00249-2","article-title":"Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med [Internet]"},{"key":"10.1016\/j.jcf.2024.10.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation","author":"Oren","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.10.004_bib0015","article-title":"Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- >T Cystic Fibrosis Patients","author":"Ozeri-Galai","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jcf.2024.10.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2023.2266361","article-title":"The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1\/2 clinical study","author":"Friedman","year":"2023","journal-title":"Expert Opinion On Drug Metabolism and Toxicology"},{"issue":"6","key":"10.1016\/j.jcf.2024.10.004_bib0017","first-page":"859","article-title":"Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis","volume":"122","author":"Nickerson","year":"1980","journal-title":"American Review of Respiratory Disease"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:11:36Z","timestamp":1738257096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017983"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}